



Mylan Chosen To Testify Before Congress Concerning Authorized Generics, Citizen Petitions, Declaratory Judgments And Issues Concerning The Delay Of Generic Pharmaceutical Approvals

What: Mylan Laboratories Inc. (NYSE: MYL) has accepted an invitation to testify before the U.S. Senate Special Committee on Aging during its hearing titled "The Generic Drug Maze: Speeding Access to Affordable, Life Saving Drugs."

Mylan was invited by Sen. Gordon Smith, Ore., chairman of the committee, and Sen. Herb Kohl, Wis., ranking member of the committee.

Heather Bresch, Mylan's senior vice president of strategic corporate development in the Office of the CEO, will testify on behalf of Mylan. As part of Mylan's testimony, Ms. Bresch will address impediments that unfairly delay or hinder consumer access to affordable generic pharmaceuticals including authorized generics during the 180-day exclusivity period, citizen petitions and declaratory judgments.

Other members of the committee include Sens. Richard Shelby, Ind., Susan Collins, Maine, James Talent, Mo., Elizabeth Dole, N.C., Mel Martinez, Fla., Larry Craig, Idaho, Rick Santorum, Pa., Conrad Burns, Mont., Lamar Alexander, Tenn., Jim DeMint, S.C., James Jeffords, Vt., Ron Wyden, Ore., Blanche Lincoln, Ark., Evan Bayh, Ind., Thomas Carper, Del., Bill Nelson, Fla., Hillary Rodham Clinton, N.Y., and Ken Salazar, Colo.

When: Thursday, July 20, 2006 at 10 a.m.

Where: Dirksen Senate Office Building, Washington, D.C., Room 106

Contacts:

Mylan: Patrick Fitzgerald

724-514-1811

Patrick.Fitzgerald@mylanlabs.com

Senator Kohl: Joe Bonfiglio

202-224-2534

SOURCE Mylan Laboratories Inc.

07/18/2006 P

PRNewswire-FirstCall -- July 18

Web site: <http://www.mylan.com>

(MYL)